March 12, 2015 – Response Biomedical Corp.
Vancouver, British Columbia, March 12, 2015 – Response Biomedical Corp. (“Response”) (TSX: RBM, OTCQB: RPBIF) will release its fourth quarter and fiscal year 2014 financial results after the markets close on Monday, March 16, 2015.
Dr. Tony Holler, Interim Chief Executive Officer, will host a conference call shortly following the release of the financial results on March 16, 2015 at 2:00 p.m. PDT (5:00 p.m. EDT) to discuss these financial results for the fourth quarter and fiscal year 2014. Participating in the call will be Bill Adams, Chief Financial Officer.
The conference call will be webcast live and is also available by dialing 1- 877-643-7155 in North America or 1- 914-495-8552 for all other locations. The conference ID number is 86841950 and participants are encouraged to initiate their calls at least 10 minutes in advance of the 2:00 p.m. PDT (5:00 p.m. EDT) start time to ensure a timely connection.
The live webcast and earnings release will be accessible from our website: http://responsebio.com/investors/presentations. A replay of the conference call will also be available online approximately two hours after the call and for 90 days thereafter.
About Response Biomedical Corp.
Response develops, manufactures and markets rapid onsite diagnostic tests for use with its RAMP® platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® platform consists of a reader and single use disposable test cartridges and has the potential to be adapted to any other medical and nonmedical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, thromboembolism and infectious diseases. In the nonclinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus antigen and for Biodefense applications including the rapid onsite detection of anthrax, smallpox, ricin and botulinum toxin. Response is a publicly traded company listed on the TSX under the trading symbol “RBM” and quoted on the OTCQB under the symbol “RPBIF”. For further information, please visit the Company’s website at www.responsebio.com.
For further information, please contact:
Response Biomedical Corp.
W.J. (Bill) Adams, 604-456-6010
Chief Financial Officer